Letter from the Editor

Introduction.

Dear colleagues,

I am delighted to present you the 2021 ASCO GI Medicom Conference Report. I am sure you will find this report as interesting as I do.

Once disease entities difficult to treat, we are getting better in managing biliary and hepatocellular cancer as our arsenal gets broader – provided, the target is there. Targeted agents and immunotherapy also make some progress in gastrointestinal cancers.

Predictive markers get closer to clinical practice – maybe soon including the gut microbioma! Please also note the prognostic importance of tumor implant number in colorectal cancer, which may lead to changes in the next TNM classification..

… and after decades we will maybe finally get something to do with oxaliplatin-induced polyneuropathy (well, modest as it may be)?

As always, there’s a lot more you should know by tomorrow morning.

Please enjoy the read.

Yours,
Stefan Rauh

Biography.

Dr Stefan Rauh is currently working as haemato-oncologist in the oncology department of Centre Hospitalier Emile Mayrisch, Esch, Luxembourg. He is mainly involved in clinical work but also in research and teaching activities and is interested in public policy and international cooperation projects in oncology. He is member of the ESMO Practicing Oncologist’s Working Group since 2011 (chair 2014-2018), member of the ESMO Public Policy Committee, and has been an ESMO Executive Board member in 2015-2016. He is co-author of the 2017 ESMO European Cancer Patient Coalition (ECPC) Patient Survivorship Guide and an invited expert for the ECPC.

Conflicts of interest.

Nothing to declare.

 

Copyright ©2021 Medicom Medical Publishers



Posted on 12 March 202118 June 2021